Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 hot stocks to buy with the highest upside potential. On February 9, Sami Corwin from William Blair maintained a Buy rating on Beam Therapeutics. This maintained rating reinforced the bullish outlook that the analyst previously gave on Beam Therapeutics Inc. (NASDAQ:BEAM) in a January 21 note. Corwin noted that the existing clinical data on the lead program of Beam Therapeutics Inc. (NASDAQ:BEAM), the BEAM-302 treatment for alpha-1 antitrypsin deficiency, is an important foundation that supports continued confidence in the program’s trajectory.

The analyst also urged investors to watch the early 2026 clinical data update for BEAM-302, which he sees as a key catalyst for the stock. He highlights the alignment between Beam Therapeutics Inc. (NASDAQ:BEAM) and the FDA on a potential accelerated approval pathway based on 12-month biomarker data as an important de-risking step, offering a clearer and possibly faster regulatory route. Combined with strengthening clinical evidence and clearly defined upcoming milestones, this supportive regulatory backdrop reinforces his positive stance on the company and underpins his Buy rating.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company that develops an integrated platform for precision genetic medicines.

While we acknowledge the potential of BEAM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Stocks Under $3 to Buy Right Now and  10 Best High-Upside Materials Stocks to Buy

Disclosure: None. This article is originally published at Insider Monkey.